Clinical Application of Serum Pepsinogen I and II Levels for Mass Screening to Detect Gastric Cancer

@inproceedings{Miki1993ClinicalAO,
  title={Clinical Application of Serum Pepsinogen I and II Levels for Mass Screening to Detect Gastric Cancer},
  author={Kazumasa Miki and Masao Ichinose and Koichi B Ishikawa and Naohisa Yahagi and Masashi Matsushima and Nobuyuki Kakei and Shinko Tsukada and Masahiro Kido and Satoshi Ishihama and Yasuhito Shimizu and Takehisa Suzuki and Kiyoshi Kurokawa},
  booktitle={Japanese journal of cancer research : Gann},
  year={1993}
}
A considerable number of gastric cancers derive from stomach mucosa where chronic atrophic gastritis is severe and extensive. Based on the fact that the serum pepsinogen levels provide a precise measure of the extent of chronic atrophic gastritis, we have devised a mass screening method involving serum pepsinogen measurement to identify subjects at high risk of gastric cancer. In 1991, we screened 4,647 workers (male: 4,113, female: 534, mean age: 49.0 years) at a Japanese company using this… CONTINUE READING